These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 4039984)
61. Clinical pharmacology of intracarotid etoposide. Savaraj N; Feun LG; Lu K; Wallace S; Fields WS; Loo TL Cancer Chemother Pharmacol; 1986; 16(3):292-4. PubMed ID: 3698170 [TBL] [Abstract][Full Text] [Related]
62. Ovarian dysfunction in patients with gestational trophoblastic neoplasia treated with short intensive courses of etoposide (VP-16-213). Choo YC; Chan SY; Wong LC; Ma HK Cancer; 1985 May; 55(10):2348-52. PubMed ID: 2985232 [TBL] [Abstract][Full Text] [Related]
63. [Phase I study of an oral administration of VP 16-213]. Ogawa M; Ota K; Oyama A; Fukuoka M; Takada M; Yoshida S; Sanpi K; Kimura I; Ohnoshi T; Kuraishi Y Gan To Kagaku Ryoho; 1983 Nov; 10(11):2403-7. PubMed ID: 6639102 [TBL] [Abstract][Full Text] [Related]
64. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741 [TBL] [Abstract][Full Text] [Related]
65. [Case report of choriocarcinoma of testicular origin indicating marked efficacy of a combination chemotherapy of methotrexate, vincristine, actinomycin D, cyclophosphamide, adriamycin and melphalan]. Hayashi M; Kurihara J; Takahashi H; Machida M; Kobayashi M; Yamanaka H Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):608-11. PubMed ID: 3754109 [TBL] [Abstract][Full Text] [Related]
66. Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. Yalowich JC; Ross WE Cancer Res; 1985 Apr; 45(4):1651-6. PubMed ID: 3978633 [TBL] [Abstract][Full Text] [Related]
67. Phase I clinical and pharmacokinetic study of oral etoposide phosphate. Sessa C; Zucchetti M; Cerny T; Pagani O; Cavalli F; De Fusco M; De Jong J; Gentili D; McDaniel C; Prins C J Clin Oncol; 1995 Jan; 13(1):200-9. PubMed ID: 7799021 [TBL] [Abstract][Full Text] [Related]
68. Phase I trial of a new form of an oral administration of VP-16-213. Lau ME; Hansen HH; Nissen NI; Pedersen H Cancer Treat Rep; 1979 Mar; 63(3):485-7. PubMed ID: 371801 [TBL] [Abstract][Full Text] [Related]
69. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule. Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567 [TBL] [Abstract][Full Text] [Related]
70. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer. Miller AA; Tolley EA; Niell HB Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845 [TBL] [Abstract][Full Text] [Related]
71. Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen. Ghosn M; Droz JP; Theodore C; Pico JL; Baume D; Spielmann M; Ostronoff M; Moran A; Salloum E; Kramar A Cancer; 1988 Jul; 62(1):24-7. PubMed ID: 3133101 [TBL] [Abstract][Full Text] [Related]
72. Phase I study of oral etoposide in children with refractory solid tumors. Mathew P; Ribeiro RC; Sonnichsen D; Relling M; Pratt C; Mahmoud H; Bowman L; Meyer W; Avery L; Crist W J Clin Oncol; 1994 Jul; 12(7):1452-7. PubMed ID: 8021737 [TBL] [Abstract][Full Text] [Related]
73. Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion. Montaldo PG; Figoli F; Zanette ML; Sorio R; Zucchetti M; Tirelli U; D'Incalci M Oncology; 1990; 47(1):55-61. PubMed ID: 2300386 [TBL] [Abstract][Full Text] [Related]
75. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. Loehrer PJ; Einhorn LH; Williams SD J Clin Oncol; 1986 Apr; 4(4):528-36. PubMed ID: 3633952 [TBL] [Abstract][Full Text] [Related]
76. Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). Davidson A; Gowing R; Lowis S; Newell D; Lewis I; Dicks-Mireaux C; Pinkerton CR Eur J Cancer; 1997 Oct; 33(11):1816-22. PubMed ID: 9470839 [TBL] [Abstract][Full Text] [Related]
78. Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion. Tchekmedyian NS; Egorin MJ; Cohen BE; Kaplan RS; Poplin E; Aisner J Cancer Chemother Pharmacol; 1986; 18(1):33-8. PubMed ID: 3757157 [TBL] [Abstract][Full Text] [Related]
79. [Phase II study of etoposide (VP-16-213) in genitourinary tumors. VP-16-213 Genitourinary Study Group]. Suzuki K Gan To Kagaku Ryoho; 1986 Sep; 13(9):2772-9. PubMed ID: 3753024 [TBL] [Abstract][Full Text] [Related]
80. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]